Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

TriPath/Digene

This article was originally published in The Gray Sheet

Executive Summary

PMA supplement covering use of TriPath's SurePath liquid-based cytology specimen collection medium for cervical cancer screening with Digene's Hybrid Capture 2 HPV DNA test would allow HPV testing directly from SurePath specimens. Formerly called CytoRich, SurePath preservation vials and density reagents were approved for use on the AutoCyte PREP system, now called PrepStain, via PMA supplement in May 2001. Digene announced the filing for the Hybrid Capture 2, currently approved as a follow-up to borderline Pap test results, April 16...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT016454

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel